Clinical trials: Antibody Deficiency
X-linked Agammaglobulinemia, XLA
COVID-19 Vaccine Responses in PIDD Subjects
The goal of our study is to assess the cellular immune responses of participants with antibody deficiency disease before and after immunization with SARS-CoV-2 mRNA vaccines.
- Conditions
- X-linked Agammaglobulinemia, XLA, Primary Immune Deficiency, CVID
- Trial name
- NCT05321407
- Where
- 3 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Duke University
Specific Polysaccharide Antibody Deficiency
Polysaccharide Antibody Response Study
Specific polysaccharide antibody deficiency (SPAD) is a primary immunodeficiency characterized by a deficient antibody production to capsular polysaccharides with normal total immunoglobulin levels.
- Trial name
- PARS (NCT02429531)
- Testing
- Pneumovax 23 (Sanofi Pasteur MSD), Typhim Vi (Sanofi Pasteur MSD)
- Where
- Belgium
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
COVID-19 Pandemic, D Vitamin Deficiency
Impact of Vitamin D Supplementation on COVID-19 Vaccine Response and IgG Antibodies in Deficient Women.
Decreased immunity in individuals causes a decrease in vaccine response, and vitamin D worsens this course. Vitamin D is thought to be a vitamin that can strengthen the innate immune response, inhibit the adaptive system, and…
- Conditions
- COVID-19 Pandemic, D Vitamin Deficiency, Antibody Hypersensitivity
- Trial name
- CoVıD-19 (NCT05447065)
- Testing
- Vitamin D supplement
- Where
- Turkey (Türkiye)
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Ege University
Common Variable Immune Deficiency, Specific Antibody Deficiency
Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older
Recommendations concerning the administration of Zostavax® in patients with antibody deficiency are unclear. The investigators plan to assess the immunogenicity and safety of Zostavax® in patients with antibody deficiency as…
- Conditions
- Common Variable Immune Deficiency, Specific Antibody Deficiency, X-linked Agammaglobulinemia
- Trial name
- NCT02960399
- Testing
- Zostavax®
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- University of South Florida